*ST生物：筹划收购慧泽医药51%股权

Core Viewpoint - Nanhua Biopharmaceutical Co., Ltd. plans to acquire 51% equity of Hunan Huize Biopharmaceutical Technology Co., Ltd. through a cash transaction, aiming to enhance its industry chain and establish Huize as a subsidiary [1] Group 1 - The acquisition is expected to strengthen the synergy between Nanhua and Huize, as Huize focuses on drug research and clinical evaluation, which aligns with Nanhua's business [1] - The transaction does not constitute a related party transaction and is anticipated to be classified as a major asset restructuring [1] - The intention agreement is preliminary, and the specific transaction plan is subject to negotiation, indicating uncertainty regarding the finalization of the deal [1] Group 2 - The acquisition will not involve the issuance of shares or changes in control [1] - The company will fulfill its regulatory approval and information disclosure obligations as required [1] - Investors are reminded to be aware of the associated risks [1]